← FDA DRUG APPROVALS

FDA ANDA · ANDA205230

BUTALBITAL, ASPIRIN, AND CAFFEINE

Sponsor: LGM PHARMA

APPLICATION
ANDA205230
TYPE
ANDA
ORIGINAL APPROVAL
2021-10-18
LATEST ACTION
2025-01-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

BUTALBITAL, ASPIRIN AND CAFFEINEDiscontinued
ASPIRIN 500MG, BUTALBITAL 50MG, CAFFEINE 40MG · CAPSULE · ORAL

Approval history

2025-01-21Labeling · Supplement 1 · standardAP
2021-10-18UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →